fentanyl. a synthetic opioid. president biden s new drug czar, no relation to me, told me we need to strongly employ harm use reduction, making drug use safer. they ll say look, you re enabling drug use. that s the provocation. as an evidence-based physician that has spent his career dealing with science and moving data around, we just do not have that evidence. tonight for the first time in almost 20 years, there s a new drug just approved to treat people in the early phases of al siemz ers. the first new drug approved to treat the disease since 2003. now, according to the fda, the drug can reduce the signature tangles and plaques that block the neural pathways in people
it is absolutely ridiculous. m snbc is completely out of control. there was a time when the legal process was supposed to be something safe, they didn t always come to the right verdict but hunting down jurors, trying to theohx them, they wanted to figure out who these jurors were, allegedly to contact the later but who knows, the fact is much of left-wing media is all in as activists, not reporters, you saw how they characterized kyle rittenhouse, a guy who was defending himself in the middle of a riot managed to shoot three people and what are the chances all of them, what is called now? justice and tangles persons? what were the chances? the whole thing is ridiculous. looking at this thing going on
found among more than 300 covid-19 patients, about half of them had neurological symptoms. in that first study, researchers found those symptoms of forgetfulness lasted about three to six months. then in the second study with the 158 patients who had neurological symptoms, researchers found a connection to alzheimer s disease. they looked at blood plasma samples collected from those patients and found elevated levels of certain biomarkers that are typically associated with dementia. in alzheimer s one protein can accumulate and build tangles and neurons which is a hallmark of the disease. researchers are quick to say this does not mean covid-19 causes alzheimer s. this is still early research. it was just presented.
did even in early stage patients because the controversy is there as well. there was a study done that showed it didn t work, had no effectiveness and then another study showed that it led to a 22% or associated with a 22% reduction in cognitive development. in other words, it improved things by 22%. and so that s good. but 22%, would a patient even notice that? does that translate to any kind of sort of changes in that patient s life? so the fda did two very unusual things here. one, their advisory committee months ago said essentially we don t think you should approve this drug. we don t see it as effective. they went against the advice of their advisers which hardly ever happens. the agency said, you know, we re going to approve it. when you look at studies, you can see that it reduces the amount of plaques and tangles in